BKM Wealth Management LLC Buys 3,543 Shares of Sanofi (NASDAQ:SNY)

BKM Wealth Management LLC increased its stake in shares of Sanofi (NASDAQ:SNY) by 74.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,314 shares of the company’s stock after acquiring an additional 3,543 shares during the quarter. BKM Wealth Management LLC’s holdings in Sanofi were worth $404,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rise Advisors LLC lifted its position in Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the last quarter. Salem Investment Counselors Inc. bought a new position in Sanofi during the fourth quarter valued at $27,000. Venturi Wealth Management LLC raised its stake in shares of Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after acquiring an additional 332 shares during the period. Frazier Financial Advisors LLC purchased a new stake in shares of Sanofi in the fourth quarter valued at $28,000. Finally, Register Financial Advisors LLC purchased a new stake in shares of Sanofi in the first quarter valued at $29,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 2.2 %

Shares of SNY opened at $49.59 on Tuesday. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.72. The company has a market cap of $125.60 billion, a P/E ratio of 24.92, a P/E/G ratio of 1.50 and a beta of 0.59. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company’s fifty day simple moving average is $48.68 and its 200-day simple moving average is $48.57.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, meeting the consensus estimate of $0.96. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. The business had revenue of $11.36 billion for the quarter, compared to the consensus estimate of $11.75 billion. As a group, analysts expect that Sanofi will post 4.13 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.